- What's Tisch?
- Stem Cell Trial
- Get Involved
The paper shows that MS patients receiving anti-CD20 therapy saw strong T-cell activation in response to receiving the COVID-19 vaccination, even in conditions of deficient antibody production. Furthermore, our research found no difference in patients’ T-cell response regardless of form of the disease (relapsing remitting versus progressive MS), anti-CD20 therapy administered, and type of mRNA-based vaccine administered – ultimately highlighting the need for improved understanding of T-cell response in immunocompromised individuals such as MS patients.
Additionally, by specifically investigating MS cellular immune response to mRNA vaccines, this research enhances the scientific community’s broader understanding of cellular immune response to vaccines, which has not been studied as extensively as antibody response.
Read our press release in Business Wire here.
Read the research paper in Frontiers in Immunology here.
Read the feature article in MS News Today here.
521 West 57th Street
New York, NY 10019
Support Tisch MS and our innovative research leading to treatments that improve the lives of patients.